CEO Total Pay
$6.9M
FY2022 Summary Compensation, below median
CPRX FY2022 SEC EDGAR DEF 14A
Catalyst Pharmaceuticals, Inc. CEO pay ratio
The CEO earned $6.9M in FY2022 against median worker pay of $343,631 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2023-07-12
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2022
Data updated August 2026
Subscribe to Catalyst Pharmaceuticals, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
20:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.9M
Median worker
$343,631
Latest filing FY2022. This company's newest DEF 14A on file is for FY2022, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Catalyst Pharmaceuticals, Inc. reported a 20:1 CEO-to-worker pay ratio in FY2022 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 20:1
- FY2022 disclosed
- CEO total
- $6.9M
- Summary Compensation Table total
- Median worker
- $343,631
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2022
A component-level pay breakdown is not reported in Catalyst Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Catalyst Pharmaceuticals, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2022. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 20:1
- FY2022
- vs prior FY
- +12:1
- from FY2021 8:1
- CEO $ YoY
- +234%
- $6.9M latest
- Filings shown
- 2
- FY2021–2022
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $2.1M | - | $257,525 | 8:1 | - |
| 2022 | $6.9M | +234% | $343,631 | 20:1 | +12:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1369568, FY2021–2022. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
20:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.9M
Companies in Industry
168
vs. Industry Median
Below
Catalyst Pharmaceuticals, Inc.: near-parity Item 402(u) ratio
Catalyst Pharmaceuticals, Inc. stamps FLOOR · ELITE-MED at 20:1 against $343,631 median worker pay in FY2022. the CEO earned 20× the median employee ($343,631) in FY2022.
At $343,631 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.
Pay Ratio
20:1
Below typical
What FY2022 shows for Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. stamps FLOOR · ELITE-MED at 20:1 against $343,631 median worker pay in FY2022. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Catalyst Pharmaceuticals, Inc.'s $6.9M CEO total is at or below the $7.9M industry median CEO pay.
Catalyst Pharmaceuticals, Inc. stamps FLOOR · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2022
- Total Compensation
- $6.9M
- Median Employee Pay
- $343,631
- Pay Ratio
- 20:1
- Filing Date
- 2023-07-12
Company Info
- Ticker
- CPRX
- CIK
- 1369568
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1369568, FY2022. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Catalyst Pharmaceuticals, Inc. stamps FLOOR · ELITE-MED at 20:1 against $343,631 median worker pay in FY2022.
Read with Catalyst Pharmaceuticals, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.
Artisan Partners Asset Management Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.9M (Δ $8K lighter vs Catalyst Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Factset Research Systems Inc · HEAVY
ABS(ceo_total_comp) peer at $6.9M (Δ $11K lighter vs Catalyst Pharmaceuticals, Inc.); HIGH · LOW-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Schneider National, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.9M (Δ $20K heavier vs Catalyst Pharmaceuticals, Inc.); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Pacira BioSciences, Inc. · HEAVY
ABS(ceo_total_comp) peer at $6.9M (Δ $21K lighter vs Catalyst Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Catalyst Pharmaceuticals, Inc. stamps FLOOR · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · HEAVY packages sit on the national leaderboard after reading Catalyst Pharmaceuticals, Inc..
Ratio primer · FLOOR
Catalyst Pharmaceuticals, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Catalyst Pharmaceuticals, Inc. (CIK 1369568), FY2022. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.